Scisparc Ltd. surges 10.95% amid market strength
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 30 Dec 25
Source: Coinmarketcap
Scisparc Ltd. saw a significant price increase of 10.95% in pre-market trading, as the stock crossed above its 5-day SMA. This movement aligns with the broader market context, where both the Nasdaq-100 and S&P 500 are showing slight gains of 0.01%.
The surge is attributed to broad market strength, which has positively influenced investor sentiment. As the overall market trends upward, Scisparc Ltd. benefits from this favorable environment, leading to increased buying interest in the stock.
This upward movement may indicate a growing confidence among investors in Scisparc Ltd.'s future prospects, potentially setting the stage for further gains if the market remains strong.
Analyst Views on SPRC
About SPRC
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
